These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35477536)

  • 1. Covid-19: What is the evidence for the antiviral Paxlovid?
    Extance A
    BMJ; 2022 Apr; 377():o1037. PubMed ID: 35477536
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 update: Prescription of Paxlovid by pharmacists.
    Med Lett Drugs Ther; 2022 Aug; 64(1656):e124. PubMed ID: 35921075
    [No Abstract]   [Full Text] [Related]  

  • 3. Paxlovid for treatment of COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):9-10. PubMed ID: 35134040
    [No Abstract]   [Full Text] [Related]  

  • 4. Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study.
    Buchynskyi M; Oksenych V; Kamyshna I; Kamyshnyi O
    Viruses; 2024 Jan; 16(1):. PubMed ID: 38257811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact of Paxlovid as Treatment for COVID-19, United States.
    Bai Y; Du Z; Wang L; Lau EHY; Fung IC; Holme P; Cowling BJ; Galvani AP; Krug RM; Meyers LA
    Emerg Infect Dis; 2024 Feb; 30(2):262-269. PubMed ID: 38181800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paxlovid Is Effective but Underused-Here's What the Latest Research Says About Rebound and More.
    Rubin R
    JAMA; 2024 Feb; 331(7):548-551. PubMed ID: 38294771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
    Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
    Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Paxlovid for COVID-19.
    Burki T
    Lancet Respir Med; 2022 Jul; 10(7):e68. PubMed ID: 35623373
    [No Abstract]   [Full Text] [Related]  

  • 9. Three more points about Paxlovid for covid-19.
    Phizackerley D
    BMJ; 2022 Jun; 377():o1397. PubMed ID: 35672048
    [No Abstract]   [Full Text] [Related]  

  • 10. Covid-19: NICE plans to expand Paxlovid eligibility to 1.4 million more people.
    Mahase E
    BMJ; 2024 Jan; 384():q59. PubMed ID: 38212056
    [No Abstract]   [Full Text] [Related]  

  • 11. The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits.
    Rubin R
    JAMA; 2024 Oct; 332(13):1040-1042. PubMed ID: 39240544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.
    Rubin R
    JAMA; 2022 Jun; 327(24):2380-2382. PubMed ID: 35675094
    [No Abstract]   [Full Text] [Related]  

  • 13. Covid-19: FDA authorises pharmacists to prescribe Paxlovid.
    Tanne JH
    BMJ; 2022 Jul; 378():o1695. PubMed ID: 35803606
    [No Abstract]   [Full Text] [Related]  

  • 14. A pilot study on Paxlovid therapy for hemodialysis patients with severe acute respiratory syndrome coronavirus 2 infections.
    Hao X; Bao Z; Dai R; Wu X; Li X; Zhang M; Li H; Xu L; Qiao P; Liu X; Hu W; Zhang Z; Fang J; Zhou M; Wang W; Qu J
    Front Med; 2024 Feb; 18(1):169-179. PubMed ID: 37978164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid.
    Wang Y; Chen X; Xiao W; Zhao D; Feng L
    J Infect; 2022 Nov; 85(5):e134-e136. PubMed ID: 35995309
    [No Abstract]   [Full Text] [Related]  

  • 16. Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection.
    Fishbane S; Hirsch JS; Nair V
    Am J Kidney Dis; 2022 Apr; 79(4):480-482. PubMed ID: 35032591
    [No Abstract]   [Full Text] [Related]  

  • 17. African clinical trial denied access to key COVID drug Paxlovid.
    Ledford H; Maxmen A
    Nature; 2022 Apr; 604(7906):412-413. PubMed ID: 35379975
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Paxlovid and Mortality Rates in Critically Ill Patients With COVID-19 Receiving Invasive Mechanical Ventilation: A Retrospective Cohort Study.
    Yang MJ; Jiang L; Xu L; Guo SL
    Chest; 2024 Jan; 165(1):128-131. PubMed ID: 37473858
    [No Abstract]   [Full Text] [Related]  

  • 20. Paxlovid-Tacrolimus Drug-Drug Interaction in a 23-Year-Old Female Kidney Transplant Patient with COVID-19.
    Berar Yanay N; Bogner I; Saker K; Tannous E
    Clin Drug Investig; 2022 Aug; 42(8):693-695. PubMed ID: 35816278
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.